Archives of Medicine

  • ISSN: 1989-5216
  • Journal h-index: 17
  • Journal CiteScore: 4.25
  • Journal Impact Factor: 3.58
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page


Congenital Adrenal Hyperplasia and the COVID-19 Pandemic: The Calm before the Storm

Aida Al-Jabri*

Congenital Adrenal Hyperplasia (CAH) is considered one of the most frequent autosomal recessive disorders in humans. It is a quite higher incidence in Saudi Arabia than other countries, estimated by one in 5,000 live births to one in 6400. This disease treated with lifelong cortisone (different types) and recommends increasing the hydrocortisone dose, according to the general sick day rules. The new recommended medication to treat COVID-19 patients is Dexamethasone, which is the most potent form of cortisone and it is glucocorticoid effect higher than hydrocortisone by 25 times. Till the date of write this paper, there is no published case of CAH affected with COVID-19 infection, the reason behind it is not clear but could because they are already on cortisone management.